A public stock offering from Mineralys Therapeutics of Radnor netted $192 million for the company’s development of a new blood pressure drug candidate, lorundrostat…

Mineralys Therapeutics, a Radnor biopharmaceutical company is hoping to raise $100 million to develop a new high blood pressure treatment, writes John George for Philadelphia…

When a private company goes public, it is an exciting time for investors. That is because the company will now offer an initial public offering…

Avantor, a drug-laboratory equipment and chemical supplier, began trading on the New York Stock Exchange Friday, raising about $3 billion for investors with an…